Psychopharmacology in Fragile X Syndrome - Present and Future

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 10, Issue 1, 2004, Pages 42-48

  Berry Kravis, Elizabeth ^a   Potanos, Kristina ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ampakine; FMR1; Fragile X syndrome; Medications; Psychopharmacology; Synaptic plasticity

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; GABAPENTIN; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; ANXIETY DISORDER; APPETITE DISORDER; AROUSAL; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITIVE DEFECT; COMPULSION; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISTRACTIBILITY; DRUG MECHANISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FRAGILE X SYNDROME; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HYPERACTIVITY; IMPOTENCE; IMPULSIVENESS; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; LETHARGY; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOOD DISORDER; MUSCLE HYPOTONIA; NAUSEA; NERVE CELL PLASTICITY; OBSESSIVE COMPULSIVE DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; TARDIVE DYSKINESIA; TIC; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; FORECASTING; FRAGILE X SYNDROME; HUMANS; MALE; MICE; PSYCHOPHARMACOLOGY; SEROTONIN UPTAKE INHIBITORS;

EID: 1642295079     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrdd.20007     Document Type: Review

References (45)

1. Agarwal V, Sitholey P, Kumar S, et al. 2001. Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Ment Retard 39:259-267.
2. Aman MG, Marks RE, Turbott SH, et al. 1991. The clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Pysch 30:246-256.
3. Amaria RN, Billeisen LL, Hagerman RJ. 2001. Medication use in fragile X syndrome. Mental Health Asp Dev Dis 4:89-93.
4. Arai AC, Xia YF, Rogers G, et al. 2002. Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 303:1075-1085.
5. Berry-Kravis E. 2002. Epilepsy in fragile X syndrome. Dev Med Child Neurol 44:724-728.
6. Berry-Kravis E, Grossman AW, Crnic LS, et al. 2002. Fragile X syndrome. Curr Pediatr 2:316-324.
7. Calvani M, Iddio S, De Gaetano A, et al. 2001. L-acetylcarnitine treatment on fragile X patient hyperactive behaviour. Rev Neurol Suppl 1:S65-S70.
8. Cohen IL, Tsiouris JA, Pfadt A. 1991. Effects of long-acting propanolol on agonistic and steriotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: A double-blind placebo-controlled study. J Clin Psychopharmacol 11:398-399.
9. th International Fragile X Conference, Chicago.
10. Cook EH, Jr., Rowlett R, Jaselskis C, et al. 1992. Fluoxetine treatment of children and adults with autistic disorder and metal retardation. J Am Acad Child Adolesc Psychiatry 31:739-745.
11. Granger R, Deadwyler S, Davis M, et al. 1996. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse 22:332-337.
12. Greenough WT, Klintsova AY, Irwin SA, et al. 2001. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci USA 98:7101-7106.
13. Goff DC, Leahy L, Berman I, et al. 2001. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484-487.
14. Hagerman RJ, Jackson AW, Levitas A, et al. 1986. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet 23:241-262.
15. Hagerman RJ, Murphy MA, Wittenberger MD. 1988. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 30:377-392.
16. Hagerman RJ, Fulton MJ, Leaman A, et al. 1994. Fluoxetine therapy in fragile X syndrome. Dev Brain Dys 7:155-164.
17. Hagerman RJ, Riddle JE, Roberts LS, et al. 1995. A survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dys 8:336-344.
18. Hagerman RJ, Hills J, Scharfnaker S, et al. 1999. Fragile X syndrome and selective mutism. Am J Med Genet 83:313-317.
19. Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. 2002. Influence of stimulants on electrodermal studies in Fragile X syndrome. Microsc Res Tech 57:68-73.
20. Hampson RE, Rogers G, Lynch G, et al. 1998. Facilitative effects of the ampakine CX516 on short term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18:2740-2747.
21. Handen BL, Janosky J, McAuliffe S. 1997. Long-term follow up of children with mental retardation/borderline intellectual functioning and ADHD. J Abnorm Child Psychol 25:287-295.
22. Hilton DK, Martin CA, Heffron WM, et al. 1991. Imipramine treatment of ADHD in a fragile X child. J Am Acad Child Adolesc Psychiatry 30:831-834.
23. Huber KM, Gallagher SM, Warren ST, et al. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:7746-7750.
24. Ingvar M, Ambros-Ingerson J, Davis M, et al. 1997. Enhancement by an ampakine of memory encoding in humans. Exper Neurol 146:553-559.
25. Larson J, Quach CN, LeDuc BQ, et al. 1996. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res 738:353-356.
26. th International Fragile X Conference, Chicago.
27. Li J, Pelletier MR, Perez Velazquez JL, et al. 2002. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 19:138-151.
28. Luscher C, Frerking M. 2001. Restless AMPA receptors: implications for synaptic transmission and plasticity. Trends Neurosci 24:665-670.
29. Lynch G, Granger R, Ambros-Ingerson J, et al. 1997. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exper Neurol 145:89-92.
30. Lynch G. 2002. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 5S:1035-1038.
31. Malinow R, Malenka RC. 2002. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25:103-126.
32. McCracken JT, McGough J, Shah B, et al. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321.
33. McDougle CJ, Naylor ST, Cohen DJ, et al. 1996. A double-blind placebo-controlled study of fluvoxamine in adults wit autistic disorder. Arch Gen Psychiatry 53:1001-1008.
34. Musumeci SA, Hagerman RJ, Ferri R, et al. 1999. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40:1092-1099.
35. Quirk JC, Nisenbaum ES. 2002. LY404187: A novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255-282.
36. Ratey J, Sovner R, Parks A, et al. 1991. Buspirone treatment of aggression and anxiety in mentally retarded patients: A multiple-baseline placebo lead-in study. J Clin Psychiatry 52:159-162.
37. th International Fragile X Conference, Chicago.
38. Rogan MT, Staubli UV, LeDoux JE. 1997. AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci 17:5928-5935.
39. Snyder EM, Philpot BD, Huber KM, et al. 2001. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci 4:1079-1085.
40. Staubli U, Rogers G, Lynch G. 1994. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91:777-781.
41. Strom CM, Brusca RM, Pizzi WJ. 1992. Double-blind placebo-controlled crossover study of folinic acid (Leukovorin) for the treatment of fragile X syndrome. Am J Med Genet 44:676-682.
42. Torroli MG, Vernacotola S, Mariotti P, et al. 1999. Double-blind placebo-controlled study of 1-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 87:366-368.
43. Verhoeven WM, Tuinier S. 1996. The effect of buspirone on challenging behaviour in mentally retarded patients: An open label prospective multiple-case study. J Intellect Disabil Res 40:502-508.
44. Zalfa F, Giorgi M, Primerano B, et al. 2003. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates translation of specific mRNAs at synapses. Cell 112:317-327.
45. Zubieta JK, Alessi NE. 1992. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 12:346-351.